AI News

    Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion

    Generative AI startup Profluent signs a multi-billion dollar agreement to accelerate the design of custom gene editors.

    Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion Reuters

    RT

    Reuters Technology

    Source

    Reuters Technology
    AI Analysis

    Generated insight by OnAirToday AI

    This partnership highlights how generative AI is shifting from theoretical research to high-stakes drug discovery by designing custom proteins from scratch. By leveraging deep learning, these companies are significantly accelerating the identification of precise genetic therapies that were previously difficult to engineer.

    Powered by AI • Not a substitute for human analysisMore Insights →
    Read the full story at Reuters Technology →
    Share
    Filed under:AI News

    Comments

    Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.

    0/1000